- Home
- ICCM vs IMMX Comparison
ICCM vs IMMX Comparison
Compare ICCM & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- IMMX
- Stock Information
- Founded
- ICCM 2006
- IMMX 2014
- Country
- ICCM Israel
- IMMX United States
- Employees
- ICCM N/A
- IMMX N/A
- Industry
- ICCM
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- ICCM
- IMMX Health Care
- Exchange
- ICCM Nasdaq
- IMMX Nasdaq
- Market Cap
- ICCM 61.1M
- IMMX 61.1M
- IPO Year
- ICCM N/A
- IMMX 2021
- Fundamental
- Price
- ICCM $0.83
- IMMX $2.39
- Analyst Decision
- ICCM Strong Buy
- IMMX Strong Buy
- Analyst Count
- ICCM 1
- IMMX 1
- Target Price
- ICCM $2.50
- IMMX $7.00
- AVG Volume (30 Days)
- ICCM 2.6M
- IMMX 265.9K
- Earning Date
- ICCM 08-13-2025
- IMMX 08-19-2025
- Dividend Yield
- ICCM N/A
- IMMX N/A
- EPS Growth
- ICCM N/A
- IMMX N/A
- EPS
- ICCM N/A
- IMMX N/A
- Revenue
- ICCM $3,273,000.00
- IMMX N/A
- Revenue This Year
- ICCM $75.27
- IMMX N/A
- Revenue Next Year
- ICCM $129.39
- IMMX N/A
- P/E Ratio
- ICCM N/A
- IMMX N/A
- Revenue Growth
- ICCM 0.34
- IMMX N/A
- 52 Week Low
- ICCM $0.48
- IMMX $1.26
- 52 Week High
- ICCM $1.66
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- ICCM 29.89
- IMMX 41.58
- Support Level
- ICCM $0.87
- IMMX $2.50
- Resistance Level
- ICCM $1.07
- IMMX $2.95
- Average True Range (ATR)
- ICCM 0.07
- IMMX 0.25
- MACD
- ICCM -0.02
- IMMX -0.06
- Stochastic Oscillator
- ICCM 0.26
- IMMX 4.71
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.